Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brl-15,572 SCHEMBL17978413 | 0.99 | MEN1 (1.00) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL8944148 | 0.87 | IGF1R (0.79) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL6017439 | 0.87 | KMT2A (0.76) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL19852034 | 0.77 | RECQL (0.87) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL30001848 | 0.77 | RECQL (0.87) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL17207530 | 0.76 | POLB (0.65) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL4355715 | 0.76 | MEN1 (0.62) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL27959848 | 0.76 | IGF1R (1.00) | MEN1KMT2ATSHRMAPTCYP1A2 | |
| SCHEMBL9646111 | 0.75 | ALDH1A1 (0.73) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL9374413 | 0.75 | SIGMAR1 (0.76) | TSHRMAPTLMNASIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| CN-117899219-A | Application of HTR1D as target spot in medicine for treating pain-depression co-diseases | 徐州医科大学 | 2024-04-19 | — | — | CN | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12551481-B2 | Molecular targets for addiction | THE JACKSON LABORATORY (US) | 2026-02-17 | — | — | US | disclosed |
| CN-116891405-B | Chiral alpha, alpha-diaryl ketone compound and preparation method and application thereof | 五邑大学 | 2025-12-05 | — | — | CN | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| US-20140221385-A1 | COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | CONCIT PHARMA APS (DK) | 2014-08-07 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2012163365-A1 | COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS | CONCIT PHARMA APS (DK) | 2012-12-06 | — | — | WO | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | MEN1 3426/4885KMT2A 2736/4885TSHR 3135/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | MEN1 951/4885KMT2A 1017/4885TSHR 419/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | MEN1 2593/4885KMT2A 1760/4885TSHR 417/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | MEN1 901/4885KMT2A 1091/4885TSHR 384/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | MEN1 2224/4885KMT2A 4241/4885TSHR 4673/4885 |
| US-12551481-B2 | Molecular targets for addiction | HTR1D, HTR2A, HTR1A | MEN1 3653/4885KMT2A 667/4885TSHR 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.